Management of orthostatic hypotension in patients with parkinson’s disease

Practical Neurology

Volumn 15, Issue 2, 2015, Pages 100-104

  Wu, Connie K ^a   Hohler, Anna D ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLICATION; DISEASE MANAGEMENT; HUMAN; HYPOTENSION, ORTHOSTATIC; PARKINSON DISEASE;

DISEASE MANAGEMENT; HUMANS; HYPOTENSION, ORTHOSTATIC; PARKINSON DISEASE;

EID: 84924764631     PISSN: 14747758     EISSN: 14747766     Source Type: Journal    
DOI: 10.1136/practneurol-2014-001000     Document Type: Review

References (43)

1. Velseboer DC, de Haan RJ, Wieling W, et al. Prevalence of orthostatic hypotension in Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord 2011;17:724–9.
2. Jain S, Goldstein DS. Cardiovascular dysautonomia in Parkinson disease: from pathophysiology to pathogenesis. Neurobiol Dis 2012;46:572–80.
3. Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neutrally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 2011;21:69–72.
4. Metzler M, Duerr S, Granata R, et al. Neurogenic orthostatic hypotension: pathophysiology, evaluation, and management. J Neurol 2013;260:2212–19.
5. Martí MJ, Tolosa E, Campdelacreu J. Clinical overview of the synucleinopathies. Mov Disord 2003;18:21–7.
6. Hohler AD, Amariei DE, Katz DI, et al. Treating orthostatic hypotension in patients with Parkinson’s disease and atypical Parkinsonism improves function. J Parkinsons Dis 2012;2: 235–40.
7. Shibao C, Lipsitz LA, Biaggioni I. Evaluation and treatment of orthostatic hypotension. Am J Hypertens 2013;7:317–24.
8. Mathias CJ, Young TM. Water drinking in the management of orthostatic intolerance due to orthostatic hypotension, vasovagal syncope and the postural tachycardia syndrome. Eur J Neurol 2004;11:613–19.
9. Deguchi K, Ikeda K, Sasaki I, et al. Effects of daily water drinking on orthostatic and postprandial hypotension in patients with multiple system atrophy. J Neurol 2007;254:735–40.
10. O’Donnell MJ, Yusuf S, Mente A, et al. Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA 2011;306:2229–38.
11. Denq JC, Opfer-Gehrking TL, Giuliani M, et al. Efficacy of compression of different capacitance beds in the amelioration of orthostatic hypotension. Clin Auton Res 1997;7:321–6.
12. Schoffer KL, Henderson RD, O’Maley K, et al. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson’s disease. Mov Disord 2007;22:1543–9.
13. Podoleanu C, Maggi R, Brignole M, et al. Lower limb and abdominal compression bandages prevent progressive orthostatic hypotension in elderly persons: a randomized single-blind controlled study. J Am Coll Cardiol 2006;48:1425–32.
14. Smit AAJ, Wieling W, Fujimura J, et al. Use of lower abdominal compression to combat orthostatic hypotension in patients with autonomic dysfunction. Clin Auton Res 2004;14:167–75.
15. Diedrich A, Biaggioni I. Segmental orthostatic fluid shifts. Clin Auton Res 2004;14:146–7.
16. Sánchez-Ferro A, Benito-León J, Gómez-Esteban JC. The management of orthostatic hypotension in Parkinson’s disease. Front Neurol 2013;64:1–11.
17. Chobanian AV, Volicer L, Tifft CP, et al. Mineralocorticoid-induced hypertension in patients with orthostatic hypotension. N Engl J Med 1979;301:68–73.
18. van lieshout JJ, Ten Harkel AD, Wieling W. Fludrocortisone and sleeping in the head-up position limit the postural decrease in cardiac output in autonomic failure. Clin Auton Res 2000;10:35–42.
19. Axelrod FB, Goldberg JD, Rolnitzky L, et al. Fludrocortisone in patients with familial dysautonomia—assessing effect on clinical parameters and gene expression. Clin Auton Res 2005;15:284–91.
20. Kaufmann H, Brannan T, Krakoff L, et al. Treatment of orthostatic hypotension due to autonomic failure with a peripheral alpha−adrenergic agonist (midodrine). Neurol 1988;38:951–6.
21. Low PA, Gilden JL, Freeman R, et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. JAMA 1997;277:1046–51.
22. Wright RA, Kaufmann HC, Perera R, et al. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurol 1998;51:120–4.
23. Jankovic J, Gilden JL, Hiner BC, et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med 1993;95:38–48.
24. Narabayashi H, Nakanishi T. Therapeutic effects of L-DOPS in Parkinson’s disease, double-blind comparative study against placebo as control in patients with long-term levodopa therapy. Clin Eval 1987;15:423–57.
25. Mathias CJ, Senard JM, Cortelli P. A double-blind, randomized, placebo- controlled study to determine the efficacy and safety of droxidopa in the treatment of orthostatic hypotension associated with multiple system atrophy and Parkinson’s disease. Clin Auton Res 2008;17:272.
26. Kaufmann H, Saadia D, Voustianiouk A, et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation 2003;108:724–8.
27. Goldstein DS, Holmes C, Kaufmann H, et al. Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure. Clin Auton Res 2004;14:363–8.
28. Kaufmann H, Freeman R, Biaggioni I, et al. Treatment of neurogenic orthostatic hypotension: results from a multi-center, double-blind, randomized, placebo-controlled, parallel group, induction design study. Neurol 2012;78: PL02.001.
29. Isaacson SH, Hauser RA, Szakacs CBN, et al. Impact of droxidopa treatment in patients with Parkinson’s disease and symptomatic neurogenic orthostatic hypotension (study 306). Mov Disord 2013;28(Suppl 1):468.
30. Shill H, Vernino S, Hutchman R, et al. A multicenter, open-label study to assess the long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension (NOH 304). Mov Disord 2012;27:S428.
31. Kaufmann H, Klos K, Hutchman R, et al. Effects of droxidopa (NortheraTM) on 24 hour blood pressure (BP) in patients with symptomatic neurogenic orthostatic hypotension (NOH). Mov Disord 2010;25:S405–6.
32. Biaggioni I, Low P, Rowse G, et al. Analysis of efficacy in patients with symptomatic neurogenic orthostatic hypotension treated with droxidopa and dopa-decarboxylase inhibitors. Mov Disord 2012;27:S422–3.
33. Singer W, Opfer-Gehrking TL, McPhee BR, et al. Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. J Neurol Neurosurg Psychiatry 2003;74:1294–8.
34. Singer W, Sandroni P, Opfer-Gehrking TL, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol 2006;63:513–18.
35. Pyridostigmine bromide. In: McEvoy GK. ed. AHFS drug information. Bethesda, MD: American Society of Health-System Pharmacists, Inc., 2005:1218–21.
36. Kujawa K, Leurgans S, Raman R, et al. Acute orthostatic hypotension when starting dopamine agonists in Parkinson’s disease. Arch Neurol 2000;57:1461–3.
37. Montastruc JL, Chamontin B, Senard JM, et al. Domperidone in the management of orthostatic hypotension. Clin Neuropharmacol 1985;8:191–2.
38. Rossi M, Giorgi G. Domperidone and long QTsyndrome. Curr Drug Saf 2010;5:257–62.
39. Grossman E, Rea RF, Hoffman A, et al. Yohimbine increases sympathetic nerve activity and norepinephrine spillover in normal volunteers. Am J Physiol 1991;260(Pt 2):R142–7.
40. Onrot J, Goldberg MR, Biaggioni I, et al. Oral yohimbine in human autonomic failure. Neurol 1987;37:215–20.
41. Jordan J, Shannon JR, Biaggioni I, et al. Contrasting actions of pressor agents in severe autonomic failure. Am J Med 1998;105:116–24.
42. Shibao C, Okamoto LE, Gamboa A, et al. Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure. Hypertension. 2010;56:847–51.
43. Okamoto LE, Shibao C, Gamboa A, et al. Synergistic effect of norepinephrine transporter blockade and α-2 antagonism on blood pressure in autonomic failure. Hypertension 2012;59:650–6.